JP2023516713A - アフリカ豚熱ウイルス感染に対するワクチン - Google Patents

アフリカ豚熱ウイルス感染に対するワクチン Download PDF

Info

Publication number
JP2023516713A
JP2023516713A JP2022552880A JP2022552880A JP2023516713A JP 2023516713 A JP2023516713 A JP 2023516713A JP 2022552880 A JP2022552880 A JP 2022552880A JP 2022552880 A JP2022552880 A JP 2022552880A JP 2023516713 A JP2023516713 A JP 2023516713A
Authority
JP
Japan
Prior art keywords
ep402r
gene
protein
amino acid
asf virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552880A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516713A5 (https=
Inventor
ディクソン，リンダ
レイス，アナ
ラサクリシュナン，アニュシャー
デイヴィス，シモン
ジェンク ルイ，ユエン
信二 池水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kumamoto University NUC
Original Assignee
Kumamoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by Kumamoto University NUC filed Critical Kumamoto University NUC
Publication of JP2023516713A publication Critical patent/JP2023516713A/ja
Publication of JP2023516713A5 publication Critical patent/JP2023516713A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022552880A 2020-03-06 2021-03-05 アフリカ豚熱ウイルス感染に対するワクチン Pending JP2023516713A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GB2003289.2 2020-03-06
GB2005880.6 2020-04-22
GB2005878.0 2020-04-22
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2013541.4 2020-08-28
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
PCT/GB2021/050562 WO2021176236A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (2)

Publication Number Publication Date
JP2023516713A true JP2023516713A (ja) 2023-04-20
JP2023516713A5 JP2023516713A5 (https=) 2024-03-11

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022552880A Pending JP2023516713A (ja) 2020-03-06 2021-03-05 アフリカ豚熱ウイルス感染に対するワクチン
JP2022552870A Pending JP2023516709A (ja) 2020-03-06 2021-03-05 アフリカ豚熱ウイルス感染に対するワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022552870A Pending JP2023516709A (ja) 2020-03-06 2021-03-05 アフリカ豚熱ウイルス感染に対するワクチン

Country Status (13)

Country Link
US (3) US20240293525A1 (https=)
EP (3) EP4114454A1 (https=)
JP (2) JP2023516713A (https=)
KR (2) KR20230013016A (https=)
CN (3) CN115397463A (https=)
AU (2) AU2021229654A1 (https=)
BR (2) BR112022016893A8 (https=)
CA (2) CA3170043A1 (https=)
CL (2) CL2022002412A1 (https=)
CO (2) CO2022014152A2 (https=)
MX (2) MX2022010373A (https=)
PH (2) PH12022552084A1 (https=)
WO (3) WO2021176235A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CN120282794A (zh) * 2022-08-04 2025-07-08 T·马尔科姆 针对非洲猪瘟病毒的猪的预防和感染后治疗的显性负性抗原方法
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110451A1 (en) * 2022-11-22 2024-05-30 Intervet International B.V. Attenuated african swine fever virus and use thereof in vaccine compositions
WO2024110453A1 (en) * 2022-11-22 2024-05-30 Gold Standard Diagnostics Madrid, S.A. Method for differentiating asfv infected from asfv vaccinated animals
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150165018A1 (en) * 2013-12-18 2015-06-18 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
US20170136114A1 (en) * 2014-06-19 2017-05-18 The Pirbright Institute Vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150165018A1 (en) * 2013-12-18 2015-06-18 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
US20170136114A1 (en) * 2014-06-19 2017-05-18 The Pirbright Institute Vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABRAMS CC. AND DIXON LK.: "Sequential deletion of genes from the African swine fever virus genome using the cre/loxP recombinat", VIROLOGY, vol. 433, JPN6025011406, 2012, pages 142 - 148, ISSN: 0005817540 *
CHAPMAN DAVID AG ET AL.: "Comparison of the genome sequences of nonpathogenic and pathogenic African swine fever virus isolate", J GEN VIROL, vol. 89, JPN6025038347, 2008, pages 397 - 408, ISSN: 0005817544 *
FARLOW J. ET AL.: "Intra-epidemic genome variation in highly pathogenic African swine fever virus (ASFV) from the count", VIROLOGY JOURNAL, vol. 15:190, JPN6025011408, 2018, ISSN: 0005817542 *
HUBNER A. ET AL.: "Identification and characterization of the 285L and K145R proteins of African swine fever virus", J. GEN. VIROL., vol. 100, no. 9, JPN6025011407, 2019, pages 1303 - 1314, ISSN: 0005817541 *
REIS AL. ET AL.: "Deletion of the African Swine Fever Virus Gene DP148R Does Not Reduce Virus Replication in Culture b", J VIROL, vol. 91, JPN6025038346, 2017, pages 01428 - 17, ISSN: 0005817543 *

Also Published As

Publication number Publication date
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
BR112022016893A2 (pt) 2023-01-24
CA3170058A1 (en) 2021-09-10
CN116133680A (zh) 2023-05-16
BR112022016893A8 (pt) 2023-02-28
US20240293525A1 (en) 2024-09-05
EP4114453A1 (en) 2023-01-11
WO2021176235A1 (en) 2021-09-10
CN115397463A (zh) 2022-11-25
CO2022014256A2 (es) 2022-12-30
EP4114454A1 (en) 2023-01-11
EP4114455A1 (en) 2023-01-11
WO2021176236A1 (en) 2021-09-10
US20230124042A1 (en) 2023-04-20
MX2022010372A (es) 2023-01-19
KR20230013017A (ko) 2023-01-26
AU2021229654A1 (en) 2022-11-03
CN115605223A (zh) 2023-01-13
KR20230013016A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
US20230117978A1 (en) 2023-04-20
PH12022552084A1 (en) 2024-02-26
CL2022002412A1 (es) 2023-03-03
JP2023516709A (ja) 2023-04-20
CL2022002416A1 (es) 2023-03-03
MX2022010373A (es) 2023-01-19
PH12022552086A1 (en) 2023-11-20
CO2022014152A2 (es) 2023-02-16
AU2021231402A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2023516713A (ja) アフリカ豚熱ウイルス感染に対するワクチン
JP5492418B2 (ja) ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
JP2022538673A (ja) アフリカ豚熱ワクチン
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
WO2007119279A1 (ja) コイヘルペスウイルス（ｋｈｖ）病用ｄｎａワクチン
US20250057946A1 (en) Use of interferon as an adjuvant in vaccines
WO2022071513A1 (ja) ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン
WO2023122525A1 (en) Compositions and methods for prevention of piscine myocarditis
Yao et al. The construction and immunogenicity analyses of a recombinant pseudorabies virus with porcine circovirus type 3 capsid protein co-expression
TW496897B (en) Non-splicing variants of gp350
Li et al. Development and characterization of Rift Valley fever virus-like particles
RU2725952C1 (ru) Вакцина против hev
JP2025503470A (ja) 細胞膜上に抗原を発現させるための組成物及び方法
US20100247624A1 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
KR101111998B1 (ko) 이종성 요소가 없는 ｇＭ-음성 ＥＨＶ-돌연변이체
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
CN110577585A (zh) 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用
Ndlovu Genetic characterisation of six novel African swine fever viruses isolated from a pig, warthog, wild boar, and ticks
WO2025093040A1 (zh) 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
KR20250121105A (ko) 불활성화/약독화된 병원체를 포함하는 백신을 제조하기 위한 시스템, 방법 및 조성물
WO2024258975A1 (en) Lyme disease vaccines and methods of use thereof
JP2006137724A (ja) 海産魚のマダイイリドウイルスに対するｄｎａワクチン

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221214

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317